CBD Research in Lung Cancer, Glioblastoma, and Pancreatic Cancer

Lung Cancer

A case study was published February 21 in SAGE, “Striking lung cancer response to self-administration of cannabidiol”. The study reported an 81 year old man was diagnosed with lung cancer in October 2016, after having an increased shortness of breath over a period of three weeks. Because of his age, he declined chemotherapy and radiotherapy.

Again in December 2016, the man had a CT scan which showed one of the tumors had increased in size. He again declined treatment.

Nearly a year later, in November 2017, the man received another CT scan which revealed the tumor had almost completely disappeared. Another CT scan in January 2018 showed his condition as stable.

The case report goes on to state:

On further questioning, the patient stated that he had started taking CBD… oil 2% (200 mg CBD in 10 mL) from the beginning of September 2017. He took two drops (0.06 mL, 1.32 mg CBD) twice daily for a week and then nine drops (0.3 mL, 6 mg CBD) twice daily until the end of September. Following the November 2017 CT scan, the patient started taking nine drops twice daily but had to stop around a week later. The reason behind this was that the patient did not like the taste and caused him slight nausea. He was never physically sick. There were no other changes in the patient’s diet, medication or lifestyle from September 2017.

https://journals.sagepub.com/doi/10.1177/2050313X19832160

The study refers to other cases where CBD has had anti-neoplastic effects on cancer cells, and concludes:

Further work is needed both in vitro and in vivo to better evaluate the various mechanisms of action of CBD on malignant cells, and its potential application in the treatment of not only lung cancer but also other malignancies.

https://journals.sagepub.com/doi/10.1177/2050313X19832160

Nectar Leaf CBD Hemp Extract contains 10% CBD by weight

Gliblastoma

Glioblastoma is an aggressive form of brain cancer. The median survival time is 15 to 16 months. Studies, including one published in January in the journal Oncotarget, are showing promising in vitro results when using CBD combined with other treatment.

The Oncotarget study out of Columbia University, the whole of which seems to require an advanced degree to decipher, states in near-layman’s terms in its abstract:

Despite advances in glioblastoma (GBM) therapy, prognosis of the disease remains poor with a low survival rate. Cannabidiol (CBD) can induce cell death and enhance radiosensitivity of GBM but not normal astrocytes.

http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=26582&path[]=82682

In other words, CBD can kill cancer cells and weaken them for radiation treatment. The authors of the abstract conclude by stating:

…treatment of human GBM by the triple combination (CBD, γ-irradiation and KU60019) could significantly increase cell death levels in vitro and potentially improve the therapeutic ratio of GBM.

http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=26582&path[]=82682

Pancreatic Cancer

In January, the Journal of Pancreatic Cancer published a medical research literature review exploring whether CBD as well as THC would be effective in the treatment of the cancer.

While the authors stress there have thus far been no clinical studies of cannabinoids on humans with pancreatic cancer, “cannabinol receptors have been identified in pancreatic cancer with several studies showing in vitro antiproliferative and proapoptotic effects.”

Leave a Reply

Your email address will not be published. Required fields are marked *